A citation-based method for searching scientific literature

D A Stoffers, T J Kieffer, M A Hussain, D J Drucker, S Bonner-Weir, J F Habener, J M Egan. Diabetes 2000
Times Cited: 453







List of co-cited articles
1115 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity





Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
259
7



Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
900
6

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
Niels Vrang, Jacob Jelsing, Lotte Simonsen, Andres Eskjær Jensen, Inger Thorup, Henrik Søeborg, Lotte Bjerre Knudsen. Am J Physiol Endocrinol Metab 2012
65
9

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.
Meike Körner, Martin Stöckli, Beatrice Waser, Jean Claude Reubi. J Nucl Med 2007
303
6


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
942
6


Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
Norihiko Ogawa, James F List, Joel F Habener, Takashi Maki. Diabetes 2004
127
6

Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture.
Christian Toso, Michael McCall, Juliet Emamaullee, Shaheed Merani, Joy Davis, Ryan Edgar, Rena Pawlick, Tatsuya Kin, Lotte B Knudsen, A M James Shapiro. Transpl Int 2010
65
9

Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation.
Yuval Dor, Juliana Brown, Olga I Martinez, Douglas A Melton. Nature 2004
6


Glucagon-like peptide-1 prevents beta cell glucolipotoxicity.
J Buteau, W El-Assaad, C J Rhodes, L Rosenberg, E Joly, M Prentki. Diabetologia 2004
243
6





Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Lotte Bjerre Knudsen, Lars Wichmann Madsen, Søren Andersen, Kasper Almholt, Anne S de Boer, Daniel J Drucker, Carsten Gotfredsen, Frederikke Lihme Egerod, Anne Charlotte Hegelund, Helene Jacobsen,[...]. Endocrinology 2010
341
6

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
552
6

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
K Tatarkiewicz, P Belanger, G Gu, D Parkes, D Roy. Diabetes Obes Metab 2013
40
15


Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
745
6

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
355
6


GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts.
Gang Xu, Hideaki Kaneto, Maria D Lopez-Avalos, Gordon C Weir, Susan Bonner-Weir. Diabetes Res Clin Pract 2006
82
6

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.
Krystyna Tatarkiewicz, Pamela A Smith, Emmanuel J Sablan, Clara J Polizzi, Donald E Aumann, Christiane Villescaz, Diane M Hargrove, Bronislava R Gedulin, Melissa G W Lu, Lisa Adams,[...]. Am J Physiol Endocrinol Metab 2010
77
6

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
N H Greig, H W Holloway, K A De Ore, D Jani, Y Wang, J Zhou, M J Garant, J M Egan. Diabetologia 1999
180
5

Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy.
Diva D De León, Shaoping Deng, Reza Madani, Rexford S Ahima, Daniel J Drucker, Doris A Stoffers. Diabetes 2003
131
5



Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
M A Nauck, D Wollschläger, J Werner, J J Holst, C Orskov, W Creutzfeldt, B Willms. Diabetologia 1996
240
5





Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.
Bronislava R Gedulin, Svetlana E Nikoulina, Pamela A Smith, George Gedulin, Loretta L Nielsen, Alain D Baron, David G Parkes, Andrew A Young. Endocrinology 2005
189
5

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
C M Edwards, S A Stanley, R Davis, A E Brynes, G S Frost, L J Seal, M A Ghatei, S R Bloom. Am J Physiol Endocrinol Metab 2001
352
5

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
Mathijs C Bunck, Anja Cornér, Bjorn Eliasson, Robert J Heine, Rimma M Shaginian, Marja-Riitta Taskinen, Ulf Smith, Hannele Yki-Järvinen, Michaela Diamant. Diabetes Care 2011
189
5

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
5

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
873
5

Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts.
Lei Tian, Jie Gao, Guangbin Weng, Huimin Yi, Bole Tian, Timothy D O'Brien, Zhiguang Guo. Transpl Int 2011
39
12

Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).
Rhonda D Wideman, Irene L Y Yu, Travis D Webber, C Bruce Verchere, James D Johnson, Anthony T Cheung, Timothy J Kieffer. Proc Natl Acad Sci U S A 2006
77
6

Sulfonylurea induced beta-cell apoptosis in cultured human islets.
Kathrin Maedler, Richard D Carr, Domenico Bosco, Richard A Zuellig, Thierry Berney, Marc Y Donath. J Clin Endocrinol Metab 2005
232
5

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
James Mu, John Woods, Yun-Ping Zhou, Ranabir Sinha Roy, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Cai Li, Andrew D Howard,[...]. Diabetes 2006
353
5

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
273
5

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.
N MCINTYRE, C D HOLDSWORTH, D S TURNER. Lancet 1964
563
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.